Prognostic factors of minimally invasive surgery for gastric cancer: Does robotic gastrectomy bring oncological benefit?

Table 1 Clinicopathological characteristics of the entire cohort

Variables	n = 814
Age, yr [IQR]	68[61-74]
Sex, n (%)
Male	562 (69.0)
Female	252 (31.0)
BMI, kg/m2 [IQR]	22.2 [20.0-24.1]
ASA, n (%)
1	314 (38.6)
2	396 (48.6)
3	104 (12.8)
Clinical stage, n (%)
I	558 (68.6)
II	125 (15.3)
III	121 (14.9)
IV	10 (1.2)
Neoadjuvant chemotherapy, n (%)	119 (14.6)
Neoadjuvant radiotherapy, n (%)	0 (0)
Approach, n (%)
Laparoscopic	657 (80.7)
Robotic	157 (19.3)
Type of gastrectomy, n (%)
Distal	559 (68.7)
Total	238 (29.2)
Proximal	16 (2.0)
Pylorus preserving	1 (0.1)
Lymphadenectomy, n (%)
D1+	378 (46.4)
D2	436 (53.6)
Dissected nodes, n [IQR]	38[28-48]
Tumor size, mm [IQR]	30[20-50]
pT, n (%)
1	469 (57.6)
2	87 (10.7)
3	112 (13.8)
4	138 (17.0)
CR	8 (1.0)
pN, n (%)
0	559 (68.7)
1	98 (12.0)
2	79 (9.7)
3	78 (9.6)
pStage, n (%)
I	498 (61.2)
II	160 (19.7)
III	148 (18.2)
TCRNany	8 (1.0)
WHO histologic type, n (%)
Tub/pap	402 (49.4)
Por/sig	352 (43.2)
Mixed/other	60 (7.4)
Lymphovascular invasion, n (%)	531 (65.2)
Adjuvant chemotherapy, n (%)	242 (29.7)
Adjuvant radiotherapy, n (%)	0 (0)
Morbidity (C–D grade ≥ III), n (%)	72 (8.8)
Anastomotic leakage	22 (2.7)
Pancreatic fistula	30 (3.7)

Categorical and continuous data are presented as n (%) and median [IQR], respectively. IQR: Interquartile range; ASA: American Society of Anesthesiologists; BMI: Body mass index; CR: Complete response at the primary site; C-D: Clavien-Dindo classification.